Présentation de l'entreprise
Novartis AG operates within the Healthcare sector, specifically functioning as a Drug Manufacturer specializing in the general production of pharmaceutical medicines across Switzerland and international markets. The enterprise engages in a comprehensive lifecycle of research, development, manufacturing, distribution, marketing, and sales to deliver therapeutic solutions for various medical conditions. As a significant market participant, the company commands a substantial market capitalization of $291.89B and generates annual revenue reaching $56.67B. This financial scale is supported by an extensive operational workforce comprising 75,267 employees, which underscores the organization's massive footprint and complexity within the global pharmaceutical industry. The magnitude of its market cap relative to its revenue stream indicates a high market valuation, suggesting that investors price the company based on expectations of future growth, intellectual property value, and brand strength rather than current earnings alone. Such positioning places Novartis among the largest pharmaceutical entities globally, granting it significant influence over pricing dynamics and access to global healthcare systems.
Santé financière
The company reports a trailing twelve-month revenue of $56.67B, accompanied by a net income of $13.98B and an EBITDA figure of $23.47B. The substantial difference between the total revenue and the final net income reveals a significant cost structure where operating expenses, including research and development costs, are deducted to arrive at profitability. Despite the high EBITDA, the net income demonstrates the heavy burden of non-operating expenses or taxes inherent in the pharmaceutical sector. Novartis maintains strong financial flexibility with a free cash flow of $12.12B, which provides ample liquidity to fund ongoing research initiatives, share repurchases, and debt servicing without relying solely on external financing. The profitability is further highlighted by a gross margin of 76.0%, an operating margin of 27.8%, and a profit margin of 24.7%, indicating high efficiency in converting sales into revenue before operating costs and then into final profit. On the liability side, the company holds $11.53B in cash against total debt of $35.46B, resulting in a debt-to-equity ratio of 76.17, which suggests a leveraged balance sheet typical for capital-intensive biotech firms. Short-term liquidity is assessed via a current ratio of 1.12, indicating that current assets slightly exceed current liabilities, providing a modest buffer for immediate obligations. Return on Equity stands at 30.8% while Return on Assets is 11.1%, metrics that reveal management's effectiveness in generating returns on the shareholders' capital and the total asset base respectively.
Évaluation de la valorisation
Valuation metrics indicate a trailing P/E ratio of 21.15 and a forward P/E of 15.38. The notable discrepancy between the trailing and forward P/E ratios implies that the market expects earnings growth in the future, as the forward multiple is significantly lower than the historical average. The price-to-book ratio is recorded at 6.26, indicating a substantial market premium over the company's book value, which reflects the intangible value of its patent portfolio and brand equity. Alternative valuation measures include a price-to-sales ratio of 5.15 and an EV/EBITDA of 13.33, suggesting that the market values the company based on both sales scale and earnings power relative to enterprise value. Regarding price volatility, the stock has reached a 52-week high of $170.46 and a 52-week low of $97.72. Without the exact current price to calculate a precise percentage, the range demonstrates a wide trading band where the asset fluctuates significantly year over year. The company exhibits a beta of 0.52, which signifies that the stock's price volatility is roughly half that of the broader market, making it a relatively defensive holding during periods of market turbulence.
Growth & Income
Growth dynamics are characterized by a revenue growth rate of 2.2% year-over-year and an earnings growth rate of -11.6% year-over-year. The earnings growth rate is growing slower than revenue, and specifically, earnings are currently declining, which implies that cost pressures or one-time charges may be impacting profitability more severely than top-line sales. As a dividend payer, Novartis offers a dividend yield of 3.1% with a payout ratio of 55.9%. This payout ratio is generally sustainable given the company's strong free cash flow generation, though the recent earnings decline warrants monitoring to ensure the dividend remains covered by earnings per share over time. The combination of modest revenue expansion and negative earnings growth alongside a stable dividend yield presents a profile of a mature, cash-generative business rather than a high-growth technology firm.